1-Boc-4-(1-carboxy-cyclopropyl)-piperidine

Catalog No. :
ACVMOW593
CAS No. :
1363381-63-8
Molecular Formula :
C14H23NO4
Molecular Weight :
269.34

IUPAC Name:1-(1-(tert-butoxycarbonyl)piperidin-4-yl)cyclopropane-1-carboxylic acid

1-Boc-4-(1-carboxy-cyclopropyl)-piperidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25mg95%$158.00Login to see priceIn stockInquiry
100mg95%$313.00Login to see priceIn stockInquiry
250mg95%$500.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Boc-4-(1-carboxy-cyclopropyl)-piperidine
IUPAC Name1-(1-(tert-butoxycarbonyl)piperidin-4-yl)cyclopropane-1-carboxylic acid
MDL No.MFCD22566139
Molecular FormulaC14H23NO4
Molecular Weight269.34
SMILESO=C(C1(C2CCN(C(OC(C)(C)C)=O)CC2)CC1)O
InChI KeyLJOVYTYFUPIVES-UHFFFAOYSA-N
Synonym1-Boc-4-(1-carboxy-cyclopropyl)-piperidine;1-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]cyclopropane-1-carboxylic acid;1-(1-(tert-butoxycarbonyl)piperidin-4-yl)cyclopropane-1-carboxylic acid;1-Piperidinecarboxylic acid, 4-(1-carboxycyclopropyl)-, 1-(1,1-dimethylethyl) ester;1-(1-tert-butoxycarbonyl-4-piperidyl)cyclopropanecarboxylic acid
CAS No.1363381-63-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACVMOW593 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACVMOW593 route product structure diagram
    ACVMOW5931363381-63-8 In Stock
Inquiry

2. ACVMOW593 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACVMOW593 route product structure diagram
    ACVMOW5931363381-63-8 In Stock
Inquiry

Comments (0)